Clinical Study

An Open-Label, Multicenter Phase 4 Study To Assess Disease Activity And Biomarkers Of Neuronal Damage In Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab

Posted Date: Mar 19, 2021

  • Investigator: Lawrence Goldstick
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

The primary objective of this study is to assess disease activity during treatment with ocrelizumab in minorities represented by Black/African Americans with RMS and Hispanic/Latinos with RMS.


Participant Must Be Between 18-65 And Have Been Diagnosed With Relapsing Multiple Sclerosis (Rms). Participant Must Identify As Black/African- American Or Hispanic/Latino. Patient Must Have Been On A Maximum Of 2 Prior Ms Medications.


Relapsing Multiple Sclerosis, Neurology, Ocrelizumab

For More Information:

Mikayla Hoefelrin